Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma
Status:
Completed
Trial end date:
2021-03-02
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging,
multi-center study to evaluate the clinical effects of oral administration of dexpramipexole
for 12 weeks on peripheral blood eosinophil count in subjects with eosinophilic asthma.